1. A New Spin on Antibody–Drug Conjugates: Trastuzumab-Fulvestrant Colloidal Drug Aggregates Target HER2-Positive Cells
- Author
-
Brian K. Shoichet, Molly S. Shoichet, Da Duan, Ahil N. Ganesh, and Christopher K. McLaughlin
- Subjects
Receptor, ErbB-2 ,Nanoparticle ,Protein Corona ,02 engineering and technology ,01 natural sciences ,ErbB-2 ,Engineering ,Drug Delivery Systems ,colloids ,Nanotechnology ,General Materials Science ,Bovine serum albumin ,Fulvestrant ,Cancer ,media_common ,Tumor ,Estradiol ,biology ,Drug discovery ,digestive, oral, and skin physiology ,self-assembly ,021001 nanoscience & nanotechnology ,5.1 Pharmaceuticals ,Drug delivery ,Development of treatments and therapeutic interventions ,0210 nano-technology ,Receptor ,Biotechnology ,medicine.drug ,Drug ,endocrine system ,Materials science ,media_common.quotation_subject ,Bioengineering ,Antineoplastic Agents ,Breast Neoplasms ,010402 general chemistry ,Article ,Cell Line ,protein corona ,Cell Line, Tumor ,Breast Cancer ,medicine ,Humans ,Nanoscience & Nanotechnology ,Chromatography ,Trastuzumab ,0104 chemical sciences ,Targeted drug delivery ,drug delivery ,Chemical Sciences ,biology.protein ,Biophysics ,Nanoparticles ,Generic health relevance ,cell targeting - Abstract
While the formation of colloidal aggregates leads to artifacts in early drug discovery, their composition makes them attractive as nanoparticle formulations for targeted drug delivery as the entire nanoparticle is composed of drug. The typical transient stability of colloidal aggregates has inhibited exploiting this property. To overcome this limitation, we investigated a series of proteins to stabilize colloidal aggregates of the chemotherapeutic, fulvestrant, including the following: bovine serum albumin, a generic human immunoglobulin G, and trastuzumab, a therapeutic human epidermal growth factor receptor 2 antibody. Protein coronas reduced colloid size to
- Published
- 2017